RADNOR, Pa., Oct. 11, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against DexCom, Inc. ("DexCom") (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between April 28, 2023 and July 25, 2024, inclusive (the "Class Period")  The lead plaintiff deadline is October 21, 2024.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:     If you suffered DexCom losses, you m ...

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and ...

文章核心观点 - 根据诉讼,在2024年1月8日至2024年7月25日期间(包括这两个日期),DexCom公司向投资者发布了虚假和误导性的信息,隐瞒了公司销售团队无法执行公司预期增长潜力的事实[1][3] - 当真实情况被披露时,投资者遭受了损失[3] 公司情况总结 - DexCom公司是一家医疗设备公司,主要从事糖尿病监测设备的研发和销售[1] - 2024年第二季度,DexCom公司公布了财务业绩,并下调了全年收入指引[3] - 公司在向投资者发布积极信息的同时,却隐瞒了公司销售团队无法执行公司预期增长潜力的事实[3] 诉讼情况总结 - 罗森律师事务所代表投资者提起集体诉讼,要求获得赔偿[1][3] - 投资者如果在上述时间内购买了DexCom公司的证券,可以通过或有费用安排获得赔偿,无需支付任何费用[1] - 投资者需要在2024年10月21日之前提出加入集体诉讼的申请,成为首席原告人[1]

NEW YORK, Oct. 10, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form/?id=107508&from=4CLASS PERIOD: January 8, 2024 to July 25, 2 ...

NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and ...

Is DexCom's business in trouble, or could this be a great buying opportunity for investors?A top healthcare stock to own over the years has been DexCom (DXCM 1.18%). The company makes continuous glucose monitors (CGMs) that help diabetics track their glucose levels. CGMs are necessary devices for many people, particularly those who have type 1 diabetes. And given the increasing number of people with diabetes in the world, investing in a company which makes these devices has generally proven to be a great in ...

文章核心观点 - 公司DexCom开发用于糖尿病管理的葡萄糖监测系统 [2] - 公司曾表示有能力利用其增长潜力达到预期创纪录的新患者数量,同时超过上一财年的毛利率,并扩大客户向新G7平台的转换 [2] - 公司在2024年7月25日市场收盘后宣布2024年第二季度的业绩令人失望,并将全年收入指引从43.5亿美元下调至40亿-40.5亿美元,导致公司股价大幅下跌 [2] 根据相关目录分别进行总结 诉讼概况 - 美国证券法律事务所Bleichmar Fonti & Auld LLP宣布已对DexCom公司及其高管提起诉讼 [1] - 投资者可以在2024年10月21日之前向法院申请成为该案的首席原告 [1] - 该诉讼指控DexCom违反了1934年证券交易法第10(b)条和第20(a)条 [1] 诉讼背景 - DexCom公司在2024年7月25日市场收盘后宣布第二季度业绩不佳,并大幅下调全年收入指引 [2] - 这一消息导致DexCom股价大跌38%,从每股107.85美元下跌至每股66.60美元 [2] 诉讼目的 - 鼓励投资DexCom的投资者获取更多信息,并有机会成为该案的首席原告 [1][3] - 该诉讼将代表DexCom证券投资者提起索赔 [1]

文章核心观点 - DexCom公司在2024年1月8日至7月25日期间,对投资者做出了不实和误导性的陈述 [1][3] - DexCom公司在吸引新客户方面过于乐观,同时也难以维持现有的分销渠道 [3] - 因此,DexCom公司关于其业务、运营和前景的声明都是虚假和失实的 [3] 公司情况总结 - DexCom公司是一家医疗设备公司,其主要产品是连续葡萄糖监测系统 [1] - DexCom公司在2024年1月8日至7月25日期间,对投资者做出了不实和误导性的陈述 [1][3] - DexCom公司在吸引新客户方面过于乐观,同时也难以维持现有的分销渠道 [3] - 因此,DexCom公司关于其业务、运营和前景的声明都是虚假和失实的 [3] 投资者诉讼情况 - 有投资者对DexCom公司提起证券集体诉讼 [1] - 投资者可以在2024年10月21日之前,通过Kessler Topaz Meltzer & Check, LLP律所或其他律所申请成为集体诉讼的代表原告 [4] - 作为代表原告,投资者可以代表全体集体成员指导诉讼 [4] - 无论是否担任代表原告,投资者都可以从任何潜在的赔付中获益 [4]

Their headwinds won't last forever. Stock market crashes look daunting on a chart so long as we restrict ourselves to a short time horizon. But the more we zoom out, the more they look like minor blips as equities always recover and continue their march upward. That's why investing in stocks with attractive prospects during bear markets is a good idea. There's hardly a better time to apply half of the most fundamental piece of investing advice: "Buy low." But even if we aren't in a bear market, buying share ...

NEW YORK, Oct. 05, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company's senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and ...